Report Thumbnail
Product Code QY09150124870DK
Published Date 2024/4/25
QY Research
English125 PagesGlobal

Pharmaceutical Anti-Counterfeiting Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code QY09150124870DK◆The Apr 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/4/25
QY Research
English 125 PagesGlobal

Pharmaceutical Anti-Counterfeiting Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

The global market for Pharmaceutical Anti-Counterfeiting Solution was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Anti-Counterfeiting Solution, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pharmaceutical Anti-Counterfeiting Solution by region & country, by Type, and by Application.
The Pharmaceutical Anti-Counterfeiting Solution market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Anti-Counterfeiting Solution.
Market Segmentation
By Company
SICPA
Alpvision
3M
Cypheme
Systech
Authentix
Avery Dennison Corporation
NanoMatriX
Covectra
DS Smith
NeuroTags
U-NICA
Constantia Flexibles
Arjo Solution
SafeTraces
Segment by Type:
Authentication Technology
Track & Trace Technology
Others
Segment by Application
Medical & Pharmaceutical
Package Industry
Logistics Industry
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharmaceutical Anti-Counterfeiting Solution manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pharmaceutical Anti-Counterfeiting Solution in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pharmaceutical Anti-Counterfeiting Solution in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

  • 1 Market Overview

    • 1.1 Pharmaceutical Anti-Counterfeiting Solution Product Introduction
    • 1.2 Global Pharmaceutical Anti-Counterfeiting Solution Market Size Forecast
    • 1.3 Pharmaceutical Anti-Counterfeiting Solution Market Trends & Drivers
      • 1.3.1 Pharmaceutical Anti-Counterfeiting Solution Industry Trends
      • 1.3.2 Pharmaceutical Anti-Counterfeiting Solution Market Drivers & Opportunity
      • 1.3.3 Pharmaceutical Anti-Counterfeiting Solution Market Challenges
      • 1.3.4 Pharmaceutical Anti-Counterfeiting Solution Market Restraints
    • 1.4 Assumptions and Limitations
    • 1.5 Study Objectives
    • 1.6 Years Considered

  • 2 Competitive Analysis by Company

    • 2.1 Global Pharmaceutical Anti-Counterfeiting Solution Players Revenue Ranking (2023)
    • 2.2 Global Pharmaceutical Anti-Counterfeiting Solution Revenue by Company (2019-2024)
    • 2.3 Key Companies Pharmaceutical Anti-Counterfeiting Solution Manufacturing Base Distribution and Headquarters
    • 2.4 Key Companies Pharmaceutical Anti-Counterfeiting Solution Product Offered
    • 2.5 Key Companies Time to Begin Mass Production of Pharmaceutical Anti-Counterfeiting Solution
    • 2.6 Pharmaceutical Anti-Counterfeiting Solution Market Competitive Analysis
      • 2.6.1 Pharmaceutical Anti-Counterfeiting Solution Market Concentration Rate (2019-2024)
      • 2.6.2 Global 5 and 10 Largest Companies by Pharmaceutical Anti-Counterfeiting Solution Revenue in 2023
      • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical Anti-Counterfeiting Solution as of 2023)
    • 2.7 Mergers & Acquisitions, Expansion

  • 3 Segmentation by Type

    • 3.1 Introduction by Type
      • 3.1.1 Authentication Technology
      • 3.1.2 Track & Trace Technology
      • 3.1.3 Others
    • 3.2 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type
      • 3.2.1 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (2019 VS 2023 VS 2030)
      • 3.2.2 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value, by Type (2019-2030)
      • 3.2.3 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value, by Type (%) (2019-2030)

  • 4 Segmentation by Application

    • 4.1 Introduction by Application
      • 4.1.1 Medical & Pharmaceutical
      • 4.1.2 Package Industry
      • 4.1.3 Logistics Industry
      • 4.1.4 Others
    • 4.2 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application
      • 4.2.1 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application (2019 VS 2023 VS 2030)
      • 4.2.2 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value, by Application (2019-2030)
      • 4.2.3 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value, by Application (%) (2019-2030)

  • 5 Segmentation by Region

    • 5.1 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Region
      • 5.1.1 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Region: 2019 VS 2023 VS 2030
      • 5.1.2 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Region (2019-2024)
      • 5.1.3 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Region (2025-2030)
      • 5.1.4 Global Pharmaceutical Anti-Counterfeiting Solution Sales Value by Region (%), (2019-2030)
    • 5.2 North America
      • 5.2.1 North America Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 5.2.2 North America Pharmaceutical Anti-Counterfeiting Solution Sales Value by Country (%), 2023 VS 2030
    • 5.3 Europe
      • 5.3.1 Europe Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 5.3.2 Europe Pharmaceutical Anti-Counterfeiting Solution Sales Value by Country (%), 2023 VS 2030
    • 5.4 Asia Pacific
      • 5.4.1 Asia Pacific Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 5.4.2 Asia Pacific Pharmaceutical Anti-Counterfeiting Solution Sales Value by Country (%), 2023 VS 2030
    • 5.5 South America
      • 5.5.1 South America Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 5.5.2 South America Pharmaceutical Anti-Counterfeiting Solution Sales Value by Country (%), 2023 VS 2030
    • 5.6 Middle East & Africa
      • 5.6.1 Middle East & Africa Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 5.6.2 Middle East & Africa Pharmaceutical Anti-Counterfeiting Solution Sales Value by Country (%), 2023 VS 2030

  • 6 Segmentation by Key Countries/Regions

    • 6.1 Key Countries/Regions Pharmaceutical Anti-Counterfeiting Solution Sales Value Growth Trends, 2019 VS 2023 VS 2030
    • 6.2 Key Countries/Regions Pharmaceutical Anti-Counterfeiting Solution Sales Value
    • 6.3 United States
      • 6.3.1 United States Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 6.3.2 United States Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (%), 2023 VS 2030
      • 6.3.3 United States Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application, 2023 VS 2030
    • 6.4 Europe
      • 6.4.1 Europe Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 6.4.2 Europe Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (%), 2023 VS 2030
      • 6.4.3 Europe Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application, 2023 VS 2030
    • 6.5 China
      • 6.5.1 China Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 6.5.2 China Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (%), 2023 VS 2030
      • 6.5.3 China Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application, 2023 VS 2030
    • 6.6 Japan
      • 6.6.1 Japan Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 6.6.2 Japan Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (%), 2023 VS 2030
      • 6.6.3 Japan Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application, 2023 VS 2030
    • 6.7 South Korea
      • 6.7.1 South Korea Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 6.7.2 South Korea Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (%), 2023 VS 2030
      • 6.7.3 South Korea Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application, 2023 VS 2030
    • 6.8 Southeast Asia
      • 6.8.1 Southeast Asia Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 6.8.2 Southeast Asia Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (%), 2023 VS 2030
      • 6.8.3 Southeast Asia Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application, 2023 VS 2030
    • 6.9 India
      • 6.9.1 India Pharmaceutical Anti-Counterfeiting Solution Sales Value, 2019-2030
      • 6.9.2 India Pharmaceutical Anti-Counterfeiting Solution Sales Value by Type (%), 2023 VS 2030
      • 6.9.3 India Pharmaceutical Anti-Counterfeiting Solution Sales Value by Application, 2023 VS 2030

  • 7 Company Profiles

    • 7.1 SICPA
      • 7.1.1 SICPA Profile
      • 7.1.2 SICPA Main Business
      • 7.1.3 SICPA Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.1.4 SICPA Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.1.5 SICPA Recent Developments
    • 7.2 Alpvision
      • 7.2.1 Alpvision Profile
      • 7.2.2 Alpvision Main Business
      • 7.2.3 Alpvision Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.2.4 Alpvision Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.2.5 Alpvision Recent Developments
    • 7.3 3M
      • 7.3.1 3M Profile
      • 7.3.2 3M Main Business
      • 7.3.3 3M Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.3.4 3M Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.3.5 Cypheme Recent Developments
    • 7.4 Cypheme
      • 7.4.1 Cypheme Profile
      • 7.4.2 Cypheme Main Business
      • 7.4.3 Cypheme Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.4.4 Cypheme Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.4.5 Cypheme Recent Developments
    • 7.5 Systech
      • 7.5.1 Systech Profile
      • 7.5.2 Systech Main Business
      • 7.5.3 Systech Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.5.4 Systech Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.5.5 Systech Recent Developments
    • 7.6 Authentix
      • 7.6.1 Authentix Profile
      • 7.6.2 Authentix Main Business
      • 7.6.3 Authentix Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.6.4 Authentix Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.6.5 Authentix Recent Developments
    • 7.7 Avery Dennison Corporation
      • 7.7.1 Avery Dennison Corporation Profile
      • 7.7.2 Avery Dennison Corporation Main Business
      • 7.7.3 Avery Dennison Corporation Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.7.4 Avery Dennison Corporation Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.7.5 Avery Dennison Corporation Recent Developments
    • 7.8 NanoMatriX
      • 7.8.1 NanoMatriX Profile
      • 7.8.2 NanoMatriX Main Business
      • 7.8.3 NanoMatriX Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.8.4 NanoMatriX Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.8.5 NanoMatriX Recent Developments
    • 7.9 Covectra
      • 7.9.1 Covectra Profile
      • 7.9.2 Covectra Main Business
      • 7.9.3 Covectra Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.9.4 Covectra Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.9.5 Covectra Recent Developments
    • 7.10 DS Smith
      • 7.10.1 DS Smith Profile
      • 7.10.2 DS Smith Main Business
      • 7.10.3 DS Smith Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.10.4 DS Smith Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.10.5 DS Smith Recent Developments
    • 7.11 NeuroTags
      • 7.11.1 NeuroTags Profile
      • 7.11.2 NeuroTags Main Business
      • 7.11.3 NeuroTags Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.11.4 NeuroTags Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.11.5 NeuroTags Recent Developments
    • 7.12 U-NICA
      • 7.12.1 U-NICA Profile
      • 7.12.2 U-NICA Main Business
      • 7.12.3 U-NICA Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.12.4 U-NICA Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.12.5 U-NICA Recent Developments
    • 7.13 Constantia Flexibles
      • 7.13.1 Constantia Flexibles Profile
      • 7.13.2 Constantia Flexibles Main Business
      • 7.13.3 Constantia Flexibles Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.13.4 Constantia Flexibles Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.13.5 Constantia Flexibles Recent Developments
    • 7.14 Arjo Solution
      • 7.14.1 Arjo Solution Profile
      • 7.14.2 Arjo Solution Main Business
      • 7.14.3 Arjo Solution Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.14.4 Arjo Solution Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.14.5 Arjo Solution Recent Developments
    • 7.15 SafeTraces
      • 7.15.1 SafeTraces Profile
      • 7.15.2 SafeTraces Main Business
      • 7.15.3 SafeTraces Pharmaceutical Anti-Counterfeiting Solution Products, Services and Solutions
      • 7.15.4 SafeTraces Pharmaceutical Anti-Counterfeiting Solution Revenue (US$ Million) & (2019-2024)
      • 7.15.5 SafeTraces Recent Developments

  • 8 Industry Chain Analysis

    • 8.1 Pharmaceutical Anti-Counterfeiting Solution Industrial Chain
    • 8.2 Pharmaceutical Anti-Counterfeiting Solution Upstream Analysis
      • 8.2.1 Key Raw Materials
      • 8.2.2 Raw Materials Key Suppliers
      • 8.2.3 Manufacturing Cost Structure
    • 8.3 Midstream Analysis
    • 8.4 Downstream Analysis (Customers Analysis)
    • 8.5 Sales Model and Sales Channels
      • 8.5.1 Pharmaceutical Anti-Counterfeiting Solution Sales Model
      • 8.5.2 Sales Channel
      • 8.5.3 Pharmaceutical Anti-Counterfeiting Solution Distributors

  • 9 Research Findings and Conclusion

  • 10 Appendix

    • 10.1 Research Methodology
      • 10.1.1 Methodology/Research Approach
      • 10.1.2 Data Source
    • 10.2 Author Details
    • 10.3 Disclaimer
USD 3,950 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.